The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population

References

• Soriano JB, Kendrick PJ, Paulson KR.; GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Stöber A, Lutter JI, Schwarzkopf L, et al. Impact of lung function and exacerbations on health-related quality of life in COPD Patients within one year: real-world analysis based on claims data. Int J Chron Obstruct Pulmon Dis. 2021;16:2637–2651. doi:10.2147/COPD.S313711
   PubMed Web of Science ®Google Scholar
• Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics. 2005;23(4):345–363. doi:10.2165/00019053-200523040-00005
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD network registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
   PubMed Web of Science ®Google Scholar
• Zeng Y, Cai S, Chen Y, et al. Current status of the treatment of COPD in China: a multicenter prospective observational study. Int J Chron Obstruct Pulmon Dis. 2020;15:3227–3237. doi:10.2147/COPD.S274024
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: arctic an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. A Phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir Med. 2019;158:59–66. doi:10.1016/j.rmed.2019.08.010
   PubMed Web of Science ®Google Scholar
• GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2017 REPORT); 2017. Available from: https://goldcopd.org/. Accessed August 9, 2023.
   Google Scholar
• Song Q, Zhao YY, Zeng YQ, et al. The characteristics of airflow limitation and future exacerbations in different GOLD groups of COPD patients. Int J Chron Obstruct Pulmon Dis. 2021;16:1401–1412. doi:10.2147/COPD.S309267
   PubMed Web of Science ®Google Scholar
• Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020;41(3):421–438. doi:10.1016/j.ccm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Covvey JR, Mullen AB, Ryan M, et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68(10):1200–1208. doi:10.1111/ijcp.12451
   PubMed Web of Science ®Google Scholar
• Song Q, Lin L, Cheng W, et al. Clinical-functional characteristics and risk of exacerbation and mortality among more symptomatic patients with chronic obstructive pulmonary disease: a retrospective cohort study. BMJ Open. 2023;13(3):e065625. doi:10.1136/bmjopen-2022-065625
   PubMed Web of Science ®Google Scholar
• Wu YK, Su WL, Yang MC, Chen SY, Wu CW, Lan CC. Characterization associated with the frequent severe exacerbator phenotype in COPD patients. Int J Chron Obstruct Pulmon Dis. 2021;16:2475–2485. doi:10.2147/COPD.S317177
   PubMed Web of Science ®Google Scholar
• Tashiro H, Kurihara Y, Takahashi K, et al. Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2020;20(1):318. doi:10.1186/s12890-020-01362-w
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the arctic study. Int J Chron Obstruct Pulmon Dis. 2021;16:701–713. doi:10.2147/COPD.S297943
   PubMed Web of Science ®Google Scholar
• Whittaker H, Rubino A, Müllerová H, et al. Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK routine health care data study. Int J Chron Obstruct Pulmon Dis. 2022;17:427–437. doi:10.2147/COPD.S346591
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Cheng W, Duan J, Zhou A, et al. Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study. Front Pharmacol. 2021;12:53653. doi:10.3389/fphar.2021.753653
   Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60. doi:10.1016/S2213-2600(12)70052-8
   PubMed Web of Science ®Google Scholar
• Song Q, Lin L, Zhou A, et al. The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study. Ann Med. 2023;55(1):1317–1324. doi:10.1080/07853890.2023.2192519
   PubMed Web of Science ®Google Scholar